Updated on 2024/05/01

写真a

 
ANDO Yuichi
 
Organization
Nagoya University Hospital Clinical Oncology and Chemotherapy Professor
Graduate School
Graduate School of Medicine
Title
Professor
External link

Degree 1

  1. 医学博士 ( 1999.3   名古屋大学 ) 

Research Interests 1

  1. clinical oncology

Research Areas 1

  1. Others / Others  / 臨床腫瘍学

Research History 4

  1. Nagoya University   Professor

    2012.5

      More details

    Country:Japan

  2. Nagoya University

    2022.4

  3. Nagoya University

    2022.4

  4. Nagoya University   Nagoya University Hospital

    2018.8 - 2022.3

Education 2

  1. Nagoya University   Graduate School, Division of Medical Sciences

    1996.4 - 1999.3

      More details

    Country: Japan

  2. Nagoya University   Faculty of Medicine

    1984.4 - 1990.3

      More details

    Country: Japan

Professional Memberships 7

  1. 日本臨床腫瘍学会   理事

  2. 日本癌学会   評議員

  3. 日本臨床薬理学会   理事

  4. 日本がん治療学会

  5. American Society of Clinical Oncology

  6. 日本呼吸器学会

  7. 日本緩和医療学会

▼display all

Awards 1

  1. 日本癌学会奨励賞

    2004  

     More details

    Country:Japan

 

Papers 111

  1. Consent in Pharmacogenetic Testing.

    Ando Y, Terada T

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology   Vol. 41 ( 22 ) page: 3875 - +   2023.8

     More details

  2. Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

    Ando, Y; Nishiyama, H; Shimodaira, H; Takano, N; Sakaida, E; Matsumoto, K; Nakanishi, K; Sakai, H; Tsukamoto, S; Komine, K; Yasuda, Y; Kato, T; Fujiwara, Y; Koyama, T; Kitamura, H; Kuwabara, T; Yonezawa, A; Okumura, Y; Yakushijin, K; Nozawa, K; Goto, H; Matsubara, T; Hoshino, J; Yanagita, M

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   Vol. 28 ( 10 ) page: 1315 - 1332   2023.10

     More details

  3. A nationwide, cross-sectional, web-based survey on healthcare providers' knowledge about, attitudes toward, and perceived barriers to adherence to clinical practice guidelines for anticancer drug therapy for older patients with cancer in Japan

    Matsuoka, A; Shimazu, T; Takahashi, M; Nagashima, F; Nishiyama, H; Fujimori, M; Ando, Y

    JOURNAL OF GERIATRIC ONCOLOGY   Vol. 14 ( 1 ) page: 101399   2023.1

     More details

  4. A rapid and durable response to larotrectinib in a patient with <i>NTRK</i> fusion-positive secretory carcinoma originating from the external auditory canal

    Ando, Y; Morita, S; Shimokata, T; Tsuzuki, T; Inafuku, S; Iwami, K; Brega, N; Akagawa, T; Tsujino, T; Ogawa, T

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 4 ) page: 242 - 246   2022.10

     More details

  5. Outcomes of immune checkpoint inhibitor-induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team

    Ito, T; Mizuno, K; Yamamoto, T; Yasuda, T; Yokoyama, S; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Hama, M; Kataoka, T; Shimokata, T; Ando, Y; Kawashima, H

    HEPATOLOGY RESEARCH     2024.4

     More details

  6. Long-term response to MEK inhibitor monotherapy in a patient with papillary thyroid carcinoma harboring <i>BRAF</i><SUP>V600E</SUP> mutation

    Takano, Y; Shimokata, T; Urakawa, H; Kikumori, T; Ando, Y

    INTERNATIONAL CANCER CONFERENCE JOURNAL     2024.4

  7. Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review

    Ushijima, F; Hase, T; Yamashita, Y; Kim, H; Shimokata, T; Kondo, C; Sato, T; Baba, T; Watanabe, S; Futamura, K; Ando, Y; Mizuno, M; Ishii, M

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 13 ( 2 ) page: 88 - 92   2024.4

     More details

  8. Efficacy and Safety of Anti-angiogenic Agents for Cancer Patients With Proteinuria or a History of Proteinuria: A Systematic Review

    Kato, T; Kurasawa, S; Takezawa, K; Fujiwara, Y; Yasuda, Y; Ando, Y

    ANTICANCER RESEARCH   Vol. 44 ( 3 ) page: 889 - 894   2024.3

     More details

  9. Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022

    Yanagita, M; Muto, S; Nishiyama, H; Ando, Y; Hirata, S; Doi, K; Fujiwara, Y; Hanafusa, N; Hatta, T; Hoshino, J; Ichioka, S; Inoue, T; Ishikura, K; Kato, T; Kitamura, H; Kobayashi, Y; Koizumi, Y; Kondoh, C; Matsubara, T; Matsubara, K; Matsumoto, K; Okuda, Y; Okumura, Y; Sakaida, E; Shibagaki, Y; Shimodaira, H; Takano, N; Uchida, A; Yakushijin, K; Yamamoto, T; Yamamoto, K; Yasuda, Y; Oya, M; Okada, H; Nangaku, M; Kashihara, N

    CLINICAL AND EXPERIMENTAL NEPHROLOGY   Vol. 28 ( 2 ) page: 85 - 122   2024.2

     More details

  10. Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer

    Liang, Y; Maeda, O; Miyata, K; Kanda, M; Sugita, S; Shimizu, D; Nishida, K; Kodera, Y; Ando, Y

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   Vol. 93 ( 2 ) page: 121 - 127   2024.2

     More details

  11. Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022 (oct, 10.1007/s10157-023-02415-0, 2022)

    Yanagita, M; Muto, S; Nishiyama, H; Ando, Y; Hirata, S; Doi, K; Fujiwara, Y; Hanafusa, N; Hatta, T; Hoshino, J; Ichioka, S; Inoue, T; Ishikura, K; Kato, T; Kitamura, H; Kobayashi, Y; Koizumi, Y; Kondoh, C; Matsubara, T; Matsubara, K; Matsumoto, K; Okuda, Y; Okumura, Y; Sakaida, E; Shibagaki, Y; Shimodaira, H; Takano, N; Uchida, A; Yakushijin, K; Yamamoto, T; Yamamoto, K; Yasuda, Y; Oya, M; Okada, H; Nangaku, M; Kashihara, N

    CLINICAL AND EXPERIMENTAL NEPHROLOGY   Vol. 28 ( 2 ) page: 123 - 124   2024.2

     More details

  12. Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer

    Nakanishi, K; Tanaka, C; Kanda, M; Miyata, K; Machida, N; Sakai, M; Kobayashi, D; Teramoto, H; Ishiyama, A; Sato, B; Oshima, T; Kajikawa, M; Matsushita, H; Ishigure, K; Yamashita, K; Fujitake, S; Sueoka, S; Asada, T; Shimizu, D; Sugita, S; Kuwatsuka, Y; Maeda, O; Furune, S; Murotani, K; Ando, Y; Ebata, T; Kodera, Y

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 86 ( 1 ) page: 43 - 51   2024.2

     More details

  13. Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors

    Liang, Y; Maeda, O; Ando, Y

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   Vol. 54 ( 4 ) page: 365 - 375   2024.1

     More details

  14. Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer

    Maeda, O; Furune, S; Kanda, M; Miyata, K; Shimizu, D; Sugita, S; Nishida, K; Ando, M; Kodera, Y; Ando, Y

    CANCER MEDICINE   Vol. 13 ( 2 ) page: e6974   2024.1

     More details

  15. Potential drug interactions between pazopanib and proton pump inhibitors/potassium-competitive acid blockers in patients with soft tissue sarcoma

    Liang, Y; Maeda, O; Shimokata, T; Yokota, K; Koike, H; Sakai, T; Ikuta, K; Urakawa, H; Nishida, Y; Akiyama, M; Ando, Y

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 13 ( 1 ) page: 63 - 67   2024.1

     More details

  16. Comment on: Carboplatin and irinotecan (CI) vs. Carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial

    Furune, S; Ando, Y

    LUNG CANCER   Vol. 186   page: 107416   2023.12

     More details

  17. Low Expectancy of Conversion Surgery with R0 Resection in Patients with CEA &gt; 5.0 ng/mL at the Initial RECIST Evaluation for Metastatic Gastric Cancer

    Nakanishi, K; Tanaka, C; Kanda, M; Miyata, K; Furukawa, K; Maeda, O; Shimizu, D; Sugita, S; Kakushima, N; Furune, S; Kawashima, H; Ando, Y; Ebata, T; Kodera, Y

    CANCERS   Vol. 15 ( 21 )   2023.11

     More details

  18. Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer

    Hatta, T; Hase, T; Hara, T; Kimura, T; Kojima, E; Abe, T; Horio, Y; Goto, Y; Ozawa, N; Yogo, N; Shibata, H; Shimokata, T; Oguri, T; Yamamoto, M; Yanagisawa, K; Ando, M; Ando, Y; Kondo, M; Ishii, M; Hasegawa, Y

    CANCER MEDICINE   Vol. 12 ( 15 ) page: 15955 - 15969   2023.8

     More details

  19. A feasibility study of modified docetaxel, cisplatin, and capecitabine for advanced gastric cancer followed by gastrectomy

    Liang, Y; Maeda, O; Miyata, K; Tanaka, C; Kanda, M; Shimizu, D; Fukaya, M; Koike, M; Kodera, Y; Ando, Y

    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY     2023.7

     More details

  20. Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis

    Yamamoto, T; Mizuno, K; Ito, T; Yokoyama, S; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Ishikawa, T; Kanamori, A; Yasuda, S; Toyoda, H; Yokota, K; Hase, T; Nishio, N; Maeda, O; Ishii, M; Sone, M; Ando, Y; Akiyama, M; Ishigami, M; Kawashima, H

    INVESTIGATIONAL NEW DRUGS   Vol. 41 ( 3 ) page: 512 - 521   2023.6

     More details

  21. Feasibility assessment of global standard chemoradiotherapy followed by surgery in patients with esophageal cancer

    Liang, Y; Maeda, O; Miyata, K; Kanda, M; Shimizu, D; Sugita, S; Okada, T; Ito, J; Kawamura, M; Ishihara, S; Nakatochi, M; Ando, M; Kodera, Y; Ando, Y

    MOLECULAR AND CLINICAL ONCOLOGY   Vol. 18 ( 4 ) page: 34   2023.4

     More details

  22. Clustering using unsupervised machine learning to stratify the risk of immune-related liver injury

    Yamamoto, T; Morooka, H; Ito, T; Ishigami, M; Mizuno, K; Yokoyama, S; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Yokota, K; Hase, T; Maeda, O; Hashimoto, N; Ando, Y; Akiyama, M; Kawashima, H

    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   Vol. 38 ( 2 ) page: 251 - 258   2023.2

     More details

  23. Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: A phase II study

    Maeda, O; Fukaya, M; Koike, M; Miyata, K; Kanda, M; Nishida, K; Ando, M; Kodera, Y; Ando, Y

    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY   Vol. 18 ( 6 ) page: 578 - 585   2022.12

     More details

  24. Selection of chemotherapy for older patients with pancreatic cancer based on geriatric assessment

    Maeda, O; Matsuoka, A; Yanagawa, M; Muroyama, Y; Watanabe, K; Liang, Y; Ishikawa, T; Ohno, E; Kawashima, H; Umegaki, H; Kuzuya, M; Ando, Y

    JOURNAL OF GERIATRIC ONCOLOGY   Vol. 13 ( 8 ) page: 1260 - 1263   2022.11

     More details

  25. A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors

    Morita, S; Minami, H; Mitsuma, A; Toyoda, M; Kiyota, N; Ando, Y

    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY   Vol. 18 ( 5 ) page: E427 - E434   2022.10

     More details

  26. Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade

    Kobayashi, T; Iwama, S; Yamagami, A; Yasuda, Y; Okuji, T; Ito, M; Zhou, X; Ando, M; Onoue, T; Miyata, T; Sugiyama, M; Hagiwara, D; Suga, H; Banno, R; Hase, T; Morise, M; Ito, T; Kikumori, T; Inoue, M; Ando, Y; Masuda, N; Kawashima, H; Hashimoto, N; Arima, H

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM   Vol. 107 ( 10 ) page: E4115 - E4123   2022.9

     More details

  27. Summary of the Clinical Practice Guidelines for Penile Cancer 2021 by the Japanese Urological Association

    Yamaguchi, T; Sugiyama, Y; Tanaka, T; Kimura, T; Yumura, Y; Nakano, M; Sugiyama, T; Miura, N; Goya, M; Yamamoto, A; Takahashi, S; Miura, Y; Tsuzuki, T; Masumori, N; Nishiyama, H; Yao, MS; Koie, T; Miyake, H; Saika, T; Saito, S; Akimoto, T; Tamada, T; Ando, Y; Takahashi, S; Suzuki, T; Hinotsu, S; Kamba, T

    INTERNATIONAL JOURNAL OF UROLOGY   Vol. 29 ( 8 ) page: 780 - 792   2022.8

     More details

  28. Clinical impact of standardized creatinine on dose adjustment of capecitabine

    Ito, A; Ichikawa, K; Miyazaki, M; Sagara, A; Motegi, T; Ando, Y; Senzaki, K; Nagai, T; Yamada, K

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 84 ( 3 ) page: 547 - 553   2022.8

     More details

  29. Direct Observation of Retinal Microvessels in Cancer Patients After Systemic Administration of Bevacizumab and Oxaliplatin.

    Mitsuma A, Ito Y, Shimokata T, Tanaka C, Uehara K, Nakayama G, Terasaki H, Ando Y

    Cancer diagnosis & prognosis   Vol. 2 ( 3 ) page: 330 - 335   2022.5

     More details

    Language:English  

    DOI: 10.21873/cdp.10113

    PubMed

  30. Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline

    Iwama, S; Kobayashi, T; Yasuda, Y; Okuji, T; Ito, M; Ando, M; Zhou, X; Yamagami, A; Onoue, T; Kawaguchi, Y; Miyata, T; Sugiyama, M; Takagi, H; Hagiwara, D; Suga, H; Banno, R; Hase, T; Morise, M; Wakahara, K; Yokota, K; Kato, M; Nishio, N; Tanaka, C; Miyata, K; Ogura, A; Ito, T; Sawada, T; Shimokata, T; Niimi, K; Ohka, F; Ishigami, M; Gotoh, M; Hashimoto, N; Saito, R; Kiyoi, H; Kajiyama, H; Ando, Y; Hibi, H; Sone, M; Akiyama, M; Kodera, Y; Arima, H

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM   Vol. 107 ( 4 ) page: E1620 - E1630   2022.3

     More details

  31. Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade

    Miyai, Y; Sugiyama, D; Hase, T; Asai, N; Taki, T; Nishida, K; Fukui, T; Chen-Yoshikawa, TF; Kobayashi, H; Mii, S; Shiraki, Y; Hasegawa, Y; Nishikawa, H; Ando, Y; Takahashi, M; Enomoto, A

    LIFE SCIENCE ALLIANCE   Vol. 5 ( 6 )   2022.3

     More details

  32. [Chemotherapy for Older Patients with Cancer].

    Mitsuma A, Ando Y

    Gan to kagaku ryoho. Cancer & chemotherapy   Vol. 49 ( 1 ) page: 13 - 18   2022.1

     More details

    Language:Japanese  

    PubMed

  33. Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment (Oct, 10.1007/s13691-021-00515-w, 2021)

    Furune, S; Kondo, C; Takano, Y; Shimokata, T; Sugishita, M; Mitsuma, A; Maeda, O; Ando, Y

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 1 ) page: 49 - 49   2022.1

     More details

  34. Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

    Furune, S; Kondo, C; Takano, Y; Shimokata, T; Sugishita, M; Mitsuma, A; Maeda, O; Ando, Y

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 1 ) page: 46 - 48   2022.1

     More details

  35. Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer

    Takano, Y; Furune, S; Miyai, Y; Morita, S; Inoue, M; Shimokata, T; Sugishita, M; Mitsuma, A; Maeda, O; Ando, Y

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 1 ) page: 67 - 70   2022.1

     More details

  36. COVID-19 Pandemic and Trends in Clinical Trials: A Multi-Region and Global Perspective

    Nishiwaki, S; Ando, Y

    FRONTIERS IN MEDICINE   Vol. 8   page: 812370   2021.12

     More details

  37. Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial

    Kanda, M; Shimizu, D; Miyata, K; Maeda, O; Tanaka, C; Inokawa, Y; Hattori, N; Hayashi, M; Ando, M; Kuwatsuka, Y; Murotani, K; Nakayama, G; Koike, M; Ando, Y; Ebata, T; Kodera, Y

    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS   Vol. 24   page: 100853   2021.12

     More details

  38. A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events

    Schöffski, P; Concin, N; Suarez, C; Subbiah, V; Ando, Y; Ruan, SL; Wagner, JP; Mansfield, K; Zhu, X; Origuchi, S; DiDominick, S; Bialucha, CU; Faris, JE; Tran, B

    ONCOLOGY RESEARCH AND TREATMENT   Vol. 44 ( 10 ) page: 547 - 556   2021.10

     More details

  39. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies

    Ito, T; Ishigami, M; Yamamoto, T; Mizuno, K; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Kawashima, H; Yasuda, S; Toyoda, H; Yokota, K; Hase, T; Nishio, N; Maeda, O; Kato, M; Hashimoto, N; Hibi, H; Kodera, Y; Sone, M; Ando, Y; Akiyama, M; Shimoyama, Y; Fujishiro, M

    HEPATOLOGY INTERNATIONAL   Vol. 15 ( 5 ) page: 1278 - 1287   2021.10

     More details

  40. Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review

    Kazama, S; Morimoto, R; Kimura, Y; Shibata, N; Ozaki, R; Araki, T; Mizutani, T; Oishi, H; Arao, Y; Kuwayama, T; Hiraiwa, H; Kondo, T; Furusawa, K; Shimokata, T; Okumura, T; Bando, YK; Ando, Y; Murohara, T

    CARDIO-ONCOLOGY   Vol. 7 ( 1 ) page: 26   2021.7

     More details

  41. A case of recurrent gastric cancer with drug-induced immune thrombocytopenia caused by trastuzumab

    Takano, Y; Furune, S; Morita, S; Inoue, M; Shimokata, T; Sugishita, M; Mitsuma, A; Osamu, M; Ando, Y

    ANNALS OF ONCOLOGY   Vol. 32   page: S354 - S354   2021.7

     More details

  42. Guidelines for clinical evaluation of anti-cancer drugs

    Minami, H; Kiyota, N; Kimbara, S; Ando, Y; Shimokata, T; Ohtsu, A; Fuse, N; Kuboki, Y; Shimizu, T; Yamamoto, N; Nishio, K; Kawakami, Y; Nihira, SI; Sase, K; Nonaka, T; Takahashi, H; Komori, Y; Kiyohara, K

    CANCER SCIENCE   Vol. 112 ( 7 ) page: 2563 - 2577   2021.7

     More details

  43. Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

    Wick, A; Bähr, O; Schuler, M; Rohrberg, K; Chawla, SP; Janku, F; Schiff, D; Heinemann, V; Narita, Y; Lenz, HJ; Ikeda, M; Ando, Y; Wick, W; Steinbach, JP; Burger, MC; Wenger, K; Lassen, U; Sankhala, KK; Roggia, C; Genvresse, I; Munhoz, C; Rentzsch, C; Reschke, S; Langer, S; Wagner, M; Kaulfuss, S; Cai, C; Lagkadinou, E; Jeffers, M; Peña, C; Tabatabai, G

    CLINICAL CANCER RESEARCH   Vol. 27 ( 10 ) page: 2723 - 2733   2021.5

     More details

  44. Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies

    Minami, H; Doi, T; Toyoda, M; Imamura, Y; Kiyota, N; Mitsuma, A; Shimokata, T; Naito, Y; Matsubara, N; Tajima, T; Tokushige, K; Ishihara, K; Cameron, S; Ando, Y

    CANCER SCIENCE   Vol. 112 ( 2 ) page: 725 - 733   2021.2

     More details

  45. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)

    Nakayama, G; Takano, N; Taniguchi, H; Ishigure, K; Yokoyama, H; Teramoto, H; Hashimoto, R; Sakai, M; Ishiyama, A; Kinoshita, T; Hayashi, N; Nakamura, M; Hattori, N; Sato, Y; Umeda, S; Uehara, K; Aiba, T; Sonohara, F; Hayashi, M; Kanda, M; Kobayashi, D; Tanaka, C; Yamada, S; Koike, M; Fujiwara, M; Murotani, K; Ando, M; Ando, Y; Muro, K; Kodera, Y

    EUROPEAN JOURNAL OF CANCER   Vol. 144   page: 61 - 71   2021.2

     More details

  46. Protocol for a multi-site, cluster-randomized, phase III, comparative clinical trial of geriatric assessment of older patients with non-small-cell lung cancer: the ENSURE-GA study

    Tsubata, Y; Shinomiya, S; Inoue, K; Ishikawa, N; Saito, R; Nakashima, K; Hotta, K; Hamada, A; Nagashima, F; Ando, Y; Morita, S; Kobayashi, K; Isobe, T

    BMC GERIATRICS   Vol. 21 ( 1 ) page: 74   2021.1

     More details

  47. PhaseIIclinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors

    Nishida, Y; Urakawa, H; Nakayama, R; Kobayashi, E; Ozaki, T; Ae, K; Matsumoto, Y; Tsuchiya, H; Goto, T; Hiraga, H; Naka, N; Takahashi, S; Ando, Y; Ando, M; Kuwatsuka, Y; Hamada, S; Ueda, T; Kawai, A

    INTERNATIONAL JOURNAL OF CANCER   Vol. 148 ( 1 ) page: 140 - 149   2021.1

     More details

  48. Chemotherapy for biliary tract cancer: real-world experience in a single institute

    Maeda, O; Ebata, T; Shimokata, T; Matsuoka, A; Inada-Inoue, M; Morita, S; Takano, Y; Urakawa, H; Miyai, Y; Sugishita, M; Mitsuma, A; Ando, M; Mizuno, T; Nagino, M; Ando, Y

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 82 ( 4 ) page: 725 - 733   2020.11

     More details

  49. What is the impact of systemic chemotherapy for lateral lymph nodes in patients with locally advanced low rectal cancer?

    Ogura, A; Uehara, K; Aiba, T; Hattori, N; Nakayama, G; Maeda, O; Ando, Y; Kodera, Y; Ebata, T; Nagino, M

    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE   Vol. 35 ( 11 ) page: 2073 - 2080   2020.11

     More details

  50. Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review

    Maeda, O; Ohka, F; Maesawa, S; Matsuoka, A; Shimokata, T; Mitsuma, A; Urakawa, H; Nakamura, S; Shimoyamas, Y; Nakaguro, SM; Wakabayashi, T; Ando, Y

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 82 ( 4 ) page: 631 - 644   2020.11

     More details

  51. Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial

    Nishida, Y; Hamada, S; Urakawa, H; Ikuta, K; Sakai, T; Koike, H; Ito, K; Emoto, R; Ando, Y; Matsui, S

    CANCER SCIENCE   Vol. 111 ( 11 ) page: 4187 - 4194   2020.11

     More details

  52. Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5′-Deoxy-5-fluorocytidine, and Creatinine Clearance

    Inaishi, T; Fujita, KI; Matsumoto, N; Shimokata, T; Maeda, O; Kikumori, T; Hattori, N; Nakayama, G; Ando, Y

    IN VIVO   Vol. 34 ( 6 ) page: 3539 - 3544   2020.11

     More details

  53. Gap between pediatric and adult approvals of molecular targeted drugs

    Nishiwaki, S; Ando, Y

    SCIENTIFIC REPORTS   Vol. 10 ( 1 ) page: 17145   2020.10

     More details

  54. Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer

    Minami, H; Ando, Y; Tamura, K; Tajima, T; Isaacs, R

    ANTICANCER RESEARCH   Vol. 40 ( 9 ) page: 5229 - 5235   2020.9

     More details

  55. 5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Letter

    Maeda, O; Shimokata, T; Ando, Y

    CLINICAL CANCER RESEARCH   Vol. 26 ( 14 ) page: 3889 - 3889   2020.7

     More details

  56. Experiences and hidden needs of older patients, their families and their physicians in palliative chemotherapy decision-making: a qualitative study

    Tsuboi, R; Sugishita, M; Hirakawa, Y; Ando, Y

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   Vol. 50 ( 7 ) page: 779 - 786   2020.7

     More details

  57. Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study

    Urakawa, H; Ando, Y; Hase, T; Kikumori, T; Arai, E; Maeda, O; Mitsuma, A; Sugishita, M; Shimokata, T; Ikuta, K; Ishiguro, N; Nishida, Y

    INTERNATIONAL JOURNAL OF CANCER   Vol. 146 ( 12 ) page: 3504 - 3515   2020.6

     More details

  58. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies

    Mizuno, K; Ito, T; Ishigami, M; Ishizu, Y; Kuzuya, T; Honda, T; Kawashima, H; Inukai, Y; Toyoda, H; Yokota, K; Hase, T; Maeda, O; Kiyoi, H; Nagino, M; Hibi, H; Kodera, Y; Fujimoto, Y; Sone, M; Gotoh, M; Ando, Y; Akiyama, M; Hasegawa, Y; Fujishiro, M

    JOURNAL OF GASTROENTEROLOGY   Vol. 55 ( 6 ) page: 653 - 661   2020.6

     More details

  59. Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.

    Nishida, Y; Urakawa, H; Nakayama, R; Ozaki, T; Ae, K; Matsumoto, Y; Ando, Y; Kuwatsuka, Y; Ueda, T; Kawai, A

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 38 ( 15 )   2020.5

     More details

    Language:Japanese  

    Web of Science

  60. Significance of meflin-positive cancer-associated fibroblasts in predicting response to immune checkpoint inhibitors in non-small cell lung cancer.

    Miyai, Y; Enomoto, A; Ando, Y; Takahashi, M

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 38 ( 15 )   2020.5

     More details

    Language:Japanese  

    Web of Science

  61. Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study

    Okada, N; Iwama, S; Okuji, T; Kobayashi, T; Yasuda, Y; Wada, E; Onoue, T; Goto, M; Sugiyama, M; Tsunekawa, T; Takagi, H; Hagiwara, D; Ito, Y; Suga, H; Banno, R; Hase, T; Morise, M; Kanda, M; Yokota, K; Hashimoto, N; Ando, M; Fujimoto, Y; Nagino, M; Kodera, Y; Fujishiro, M; Hibi, H; Sone, M; Kiyoi, H; Gotoh, M; Ando, Y; Akiyama, M; Hasegawa, Y; Arima, H

    BRITISH JOURNAL OF CANCER   Vol. 122 ( 6 ) page: 771 - 777   2020.3

     More details

  62. Detection of bacteria in blood circulation in patients receiving cancer chemotherapy

    Ota, A; Morita, S; Matsuoka, A; Shimokata, T; Maeda, O; Mitsuma, A; Yagi, T; Asahara, T; Ando, Y

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   Vol. 25 ( 1 ) page: 210 - 215   2020.1

     More details

  63. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study

    Kobayashi, T; Iwama, S; Yasuda, Y; Okada, N; Okuji, T; Ito, M; Onoue, T; Goto, M; Sugiyama, M; Tsunekawa, T; Takagi, H; Hagiwara, D; Ito, Y; Suga, H; Banno, R; Yokota, K; Hase, T; Morise, M; Hashimoto, N; Ando, M; Fujimoto, Y; Hibi, H; Sone, M; Ando, Y; Akiyama, M; Hasegawa, Y; Arima, H

    JOURNAL FOR IMMUNOTHERAPY OF CANCER   Vol. 8 ( 2 )   2020

     More details

  64. Application of the New Process for Unapproved Drug Use: Dilemma of Universal Health Care Coverage in Japan

    Nishiwaki, S; Ando, Y

    JOURNAL OF GLOBAL ONCOLOGY   Vol. 5   page: 1 - 3   2019.11

     More details

  65. A longitudinal tracking and quantitative assessment of paclitaxel-induced peripheral neurotoxicity

    Matsuoka, A; Mitsuma, A; Maeda, O; Tsunoda, N; Kikumori, T; Ando, Y

    ANNALS OF ONCOLOGY   Vol. 30   2019.10

     More details

    Language:Japanese  

    Web of Science

  66. Selection of chemotherapy based on geriatric assessment for elderly patients with pancreatic cancer

    Maeda, O; Matsuoka, A; Yanagawa, M; Muroyama, Y; Kuzuya, M; Ando, Y

    ANNALS OF ONCOLOGY   Vol. 30   page: 131 - 131   2019.10

     More details

    Language:Japanese  

    DOI: 10.1093/annonc/mdz343.060

    Web of Science

  67. Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours

    Wick, W; Tabatabai, G; Schuler, M; Rorhberg, K; Chawla, SP; Janku, F; Schiff, D; Heinemann, V; Narita, Y; Ando, Y; Lenz, HJ; Ikeda, M; Genvresse, I; Rentzsch, C; Reschke, S; Cyris, C; Cai, C; Jeffers, M; Pena, C; Bähr, O

    ANNALS OF ONCOLOGY   Vol. 30   page: 170 - +   2019.10

     More details

    Language:Japanese  

    Web of Science

  68. Recent progress of chemotherapy and biomarkers for gastroesophageal cancer

    Maeda, O; Ando, Y

    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY   Vol. 11 ( 7 ) page: 518 - 526   2019.7

     More details

  69. Alterations in gene expression and DNA methylation profiles in gastric cancer cells obtained from ascitic fluids collected before and after chemotherapy

    Maeda, O; Matsuoka, A; Furukawa, K; Miyahara, R; Hirooka, Y; Ando, Y

    MOLECULAR AND CLINICAL ONCOLOGY   Vol. 11 ( 1 ) page: 91 - 98   2019.7

     More details

  70. Low-dose chemotherapy with methotrexate and vinblastine for patients with refractory desmoid tumors: A second report of relationship between efficacy and various factors.

    Nishida, Y; Sakai, T; Shimizu, K; Urakawa, H; Arai, E; Ikuta, K; Ando, Y; Ishiguro, N

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 37 ( 15 )   2019.5

     More details

    Language:Japanese  

    Web of Science

  71. Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).

    Wirth, LJ; Leboulleux, S; Kiyota, N; Tahara, M; Muro, K; Ahn, MJ; Ando, Y; Taylor, MH; Takahashi, S; Kim, SB; Misir, S; Dutcus, CE; Xie, R; Joshi, PR; Hughes, BGM; Aller, J; Krzyzanowska, MK; Capdevila, J

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 37 ( 15 )   2019.5

     More details

  72. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study

    Takano, N; Yamada, S; Hirakawa, A; Yokoyama, Y; Kawashima, H; Maeda, O; Okada, T; Ohno, E; Yamaguchi, J; Ishikawa, T; Sonohara, F; Suenaga, M; Takami, H; Hayashi, M; Niwa, Y; Hirooka, Y; Ito, Y; Naganawa, S; Ando, Y; Nagino, M; Goto, H; Fuji, T; Kodera, Y

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 81 ( 2 ) page: 233 - 239   2019.5

     More details

  73. Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors

    Ando, Y; Iwasa, S; Takahashi, S; Saka, H; Kakizume, T; Natsume, K; Suenaga, N; Quadt, C; Yamada, Y

    CANCER SCIENCE   Vol. 110 ( 3 ) page: 1021 - 1031   2019.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.13923

    Web of Science

    PubMed

  74. Modified Docetaxel plus Cisplatin plus Capecitabine (DCX) for Gastric Cancer

    Maeda, O; Ando, Y; Matsuoka, A; Furukawa, K; Funasaka, K; Miyahara, R; Hirooka, Y; Goto, H

    DIGESTION   Vol. 99 ( 1 ) page: 113 - 113   2019

     More details

    Language:Japanese  

    Web of Science

  75. Spiritual pain and care needs of elderly cancer patients facing palliative chemotherapy decision-making: Qualitative study.

    Tsuboi, R; Sugishita, M; Hirakawa, H; Ando, Y

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 36 ( 34 )   2018.12

  76. Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma

    Yonemori, K; Kodaira, M; Satoh, T; Kudo, T; Takahashi, S; Nakano, K; Ando, Y; Shimokata, T; Mori, J; Inoue, K; Oakley, GJ; Sakaguchi, S; Tamura, K

    CANCER SCIENCE   Vol. 109 ( 12 ) page: 3962 - 3970   2018.12

     More details

  77. Reporting harms more transparently in trials of cancer drugs

    Gyawali, B; Shimokata, T; Honda, K; Ando, Y

    BMJ-BRITISH MEDICAL JOURNAL   Vol. 363   page: k4383   2018.11

     More details

  78. Cabozantinib in Hepatocellular Carcinoma

    Maeda Osamu, Ando Yuichi

    NEW ENGLAND JOURNAL OF MEDICINE   Vol. 379 ( 14 ) page: 1384 - 1384   2018.10

     More details

  79. Cabozantinib in Hepatocellular Carcinoma.

    Maeda O, Ando Y

    The New England journal of medicine   Vol. 379 ( 14 ) page: 1384   2018.10

     More details

  80. A longitudinal study of a new point-of-care nerve conduction device for quantitative assessment of chemotherapy-induced peripheral neurotoxicity

    Matsuoka, A; Maeda, O; Mitsuma, A; Uehara, K; Nakayama, G; Nagino, M; Kodera, Y; Ando, Y

    ANNALS OF ONCOLOGY   Vol. 29   2018.10

     More details

  81. Docetaxel, cisplatin and fluorouracil as neoadjuvant chemotherapy for esophageal cancer with prophylactic pegfilgrastim

    Maeda, O; Koike, M; Fukaya, M; Miyata, K; Iwata, N; Nagino, M; Kodera, Y; Ando, Y

    ANNALS OF ONCOLOGY   Vol. 29   2018.10

     More details

  82. Outpatient chemotherapy for patients with unresectable or metastatic bone sarcomas

    Urakawa, H; Nishida, Y; Mitsuma, A; Maeda, O; Sugishita, M; Shimokata, T; Mizutani, T; Arai, E; Ikuta, K; Hamada, S; Ota, T; Ishiguro, N; Ando, Y

    ANNALS OF ONCOLOGY   Vol. 29   2018.10

     More details

  83. Phase I study of spartalizumab (PDR001), an anti-PD1 mAb, in Japanese patients with advanced malignancies

    Ando, Y; Doi, T; Mitsuma, A; Mizutani, T; Toyoda, M; Imamura, Y; Kiyota, N; Naito, Y; Matsubara, N; Ishihara, K; Tajima, T; Tokushige, K; Cameron, S; Minami, H

    ANNALS OF ONCOLOGY   Vol. 29   2018.10

     More details

  84. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)

    Nakayama, G; Mitsuma, A; Sunagawa, Y; Ishigure, K; Yokoyama, H; Matsui, T; Nakayama, H; Nakata, K; Ishiyama, A; Asada, T; Umeda, S; Ezaka, K; Hattori, N; Takami, H; Kobayashi, D; Tanaka, C; Kanda, M; Yamada, S; Koike, M; Fujiwara, M; Fujii, T; Murotani, K; Ando, Y; Kodera, Y

    ONCOLOGIST   Vol. 23 ( 8 ) page: 919 - 927   2018.8

     More details

  85. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer

    Yamada, S; Fujii, T; Yokoyama, Y; Kawashima, H; Maeda, O; Suzuki, K; Okada, T; Ono, E; Yamaguchi, J; Takano, N; Takami, H; Hayashi, M; Niwa, Y; Hirooka, Y; Ito, Y; Naganawa, S; Ando, Y; Nagino, M; Goto, H; Kodera, Y

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   Vol. 81 ( 5 ) page: 815 - 821   2018.5

     More details

  86. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.

    Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, Takagi H, Hagiwara D, Ito Y, Morishita Y, Goto M, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Arima H

    Journal of the Endocrine Society   Vol. 2 ( 3 ) page: 241 - 251   2018.3

     More details

  87. Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial. Reviewed

    Hiroaki Tsukuura, Masayuki Miyazaki, Tatsuya Morita, Mihoko Sugishita, Hiroshi Kato, Yuka Murasaki, Bishal Gyawali, Yoko Kubo, Masahiko Ando, Masashi Kondo, Kiyofumi Yamada, Yoshinori Hasegawa and Yuichi Ando

    Oncologist   Vol. 23 ( 3 ) page: 367 - 374   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1634/theoncologist.2017-0225

    Web of Science

    PubMed

  88. Phase II trial of oral S-1 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard chemotherapies (CCOG-1105 study).

    Ezaka, K; Nakayama, G; Yokoyama, H; Matsui, T; Umeda, S; Sunagawa, Y; Murotani, K; Ando, Y; Kodera, Y

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 36 ( 4 )   2018.2

  89. Randomized phase II trial of CapOX plus bevacizumab versus CapIRI plus bevacizumab as first-line treatment in Japanese patients with metastatic colorectal cancer (CCOG-1201).

    Sasahara, M; Nakayama, G; Ishigure, K; Yokoyama, H; Uehara, K; Ishiyama, A; Matsui, T; Nakayama, H; Kobayashi, D; Umeda, S; Sunagawa, Y; Murotani, K; Ando, Y; Kodera, Y

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 36 ( 4 )   2018.2

  90. Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan. Reviewed

    Sachi Morita, Toyone Kikumori, Nobuyuki Tsunoda, Takahiro Inaishi, Yayoi Adachi, Akiko Ota, Masahiro Shibata, Ayumu Matsuoka, Kenichi Nakanishi, Dai Takeuchi, Takehumi Mizutani, Tomoya Shimokata, Hiromichi Hayashi, Osamu Maeda and Yuichi Ando

    Int J Clin Oncol   Vol. 23 ( 1 ) page: 195 - 200   2018.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10147-017-1177-z

    Web of Science

    PubMed

  91. Guidelines for treatment of renal injury during cancer chemotherapy 2016

    Horie, S; Oya, M; Nangaku, M; Yasuda, Y; Komatsu, Y; Yanagita, M; Kitagawa, Y; Kuwano, H; Nishiyama, H; Ishioka, C; Takaishi, H; Shimodaira, H; Mogi, A; Ando, Y; Matsumoto, K; Kadowaki, D; Muto, S

    CLINICAL AND EXPERIMENTAL NEPHROLOGY   Vol. 22 ( 1 ) page: 210 - 244   2018.2

     More details

  92. Clinical effectiveness of geriatric assessment for predicting the tolerability of outpatient chemotherapy in older adults with cancer. Reviewed

    Naomi Hayashi, Ayumu Matsuoka, Hidemi Goto, Momokazu Gotoh, Hitoshi Kiyoi, Yasuhiro Kodera, Masato Nagino, Fumio Nagashima, Yuichi Ando.

    J Geriatr Oncol   Vol. 9 ( 1 ) page: 84 - 86   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jgo.2017.07.014

    Web of Science

    PubMed

  93. Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan

    Maeda, O; Yokoyama, Y; Yamaguchi, J; Ota, A; Matsuoka, A; Morita, S; Inoue, M; Mizutani, T; Shimokata, T; Urakawa, H; Mitsuma, A; Nagino, M; Ando, Y

    ANNALS OF ONCOLOGY   Vol. 28   page: 69 - 69   2017.11

     More details

  94. FDA Approval Summary: Sonidegib-Letter

    Gyawali, B; Ando, Y

    CLINICAL CANCER RESEARCH   Vol. 23 ( 19 ) page: 5993 - 5993   2017.10

     More details

  95. Gemcitabine plus cisplatin and S-1 for biliary tract cancer: a single institute analysis

    Maeda, O; Shimokata, T; Mizutani, T; Inoue, M; Matsuoka, A; Ota, A; Mizuno, T; Ebata, T; Nagino, M; Ando, Y

    ANNALS OF ONCOLOGY   Vol. 28   page: 50 - 50   2017.10

     More details

  96. Correlation and differences in Effect sizes between Progression Free Survival (PFS) and Overall Survival (OS) among PD-1 inhibitors

    Gyawali, B; Shimokata, T; Ando, Y

    ANNALS OF ONCOLOGY   Vol. 28   2017.9

     More details

  97. A phase 1 study of BYL719, an a-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies

    Tomomatsu, J; Iwasa, S; Saka, H; Takahashi, S; Nakano, K; Morita, S; Inoue, M; Nakahama, H; Kogure, Y; Kakizume, T; Natsume, K; Aoki, T; Quadt, C; Yamada, Y; Ando, Y

    ANNALS OF ONCOLOGY   Vol. 28   2017.9

     More details

  98. Erratum: High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review.

    Yamamoto E, Niimi K, Fujikake K, Nishida T, Murata M, Mitsuma A, Ando Y, Kikkawa F

    Molecular and clinical oncology   Vol. 7 ( 3 ) page: 510   2017.9

     More details

  99. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)

    Nakayama, G; Ishigure, K; Yokoyama, H; Uehara, K; Kojima, H; Ishiyama, A; Hayashi, N; Takano, N; Hattori, N; Kobayashi, D; Tanaka, C; Hayashi, M; Kanda, M; Yamada, S; Sugimoto, H; Koike, M; Fujiwara, M; Fujii, T; Murotani, K; Ando, Y; Kodera, Y

    BMC CANCER   Vol. 17 ( 1 ) page: 243   2017.4

     More details

  100. Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials

    Gyawali, B; Ando, Y

    ANNALS OF ONCOLOGY   Vol. 28 ( 4 ) page: 898 - 899   2017.4

     More details

  101. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer

    Honda Kazunori, Takeshita Kyosuke, Murotani Kenta, Mitsuma Ayako, Hayashi Hironori, Tsunoda Nobuyuki, Kikumori Toyone, Murohara Toyoaki, Ando Yuichi

    BREAST CANCER   Vol. 24 ( 2 ) page: 312 - 318   2017.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12282-016-0705-4

    Web of Science

    PubMed

  102. [Nephropathy in Patients Undergoing Cancer Drug Therapy - Platinum Derivatives(Cisplatin and Carboplatin)].

    Matsuoka A, Ando Y

    Gan to kagaku ryoho. Cancer & chemotherapy   Vol. 44 ( 3 ) page: 200 - 203   2017.3

     More details

  103. Modified docetaxel, cisplatin and capecitabine for stage. gastric cancer in Japanese patients: A feasibility study

    Maeda, O; Matsuoka, A; Miyahara, R; Funasaka, K; Hirooka, Y; Fukaya, M; Nagino, M; Kodera, Y; Goto, H; Ando, Y

    WORLD JOURNAL OF GASTROENTEROLOGY   Vol. 23 ( 6 ) page: 1090 - 1097   2017.2

     More details

  104. Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials

    Gyawali, B; Shimokata, T; Ando, M; Honda, K; Ando, Y

    ANNALS OF ONCOLOGY   Vol. 28 ( 2 ) page: 246 - 253   2017.2

     More details

  105. Unconvincing Benefit of Combination TherapyWith Gefitinib and Pemetrexed in Advanced Non-Small-Cell Lung Cancer

    Ota, A; Gyawali, B; Matsuoka, A; Ando, Y

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 35 ( 6 ) page: 691 - +   2017.2

     More details

  106. [Analysis of Nedaplatin Dose in Patients with Impaired Renal Function].

    Araki R, Iwamizu H, Kataoka T, Kumakura Y, Miyazaki M, Nagai T, Ando Y, Yamada K

    Gan to kagaku ryoho. Cancer & chemotherapy   Vol. 44 ( 2 ) page: 143 - 147   2017.2

     More details

    Language:Japanese  

    PubMed

  107. Carboplatin dosing for adult Japanese patients Invited Reviewed

    Yuichi Ando, Tomoya Shimokata, Yoshinari Yasuda, and Yoshinori Hasegawa.

    Nagoya J Med Sci   Vol. 76 ( 1 ) page: 1-9   2014.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  108. A Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Reviewed

    Yuichi Ando, Megumi Inada-inoue, Ayako Mitsuma, Takayuki Yoshino, Atsushi Ohtsu, Naoko Suenaga, Masahiko Sato, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt, Toshihiko Doi.

    Cancer Sci   Vol. 105 ( 3 ) page: 347-53   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  109. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Reviewed

    Cancer Sci   Vol. 101   page: 2601-5   2010

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  110. UGT1A1*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Invited Reviewed

    Yuichi Ando, et al.

    Curr Opin Mol Ther   Vol. 9   page: 258-262   2007

     More details

    Authorship:Lead author   Language:English  

  111. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Reviewed

    Yuichi Ando, et al.

    Cancer Res   Vol. 60   page: 6921-6926   2000

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

▼display all

Books 3

  1. 高齢者のがん薬物療法ガイドライン

    統括委員長 安藤雄一

    編集:日本臨床腫瘍学会・日本癌治療学会  2019.7 

     More details

    Language:Japanese Book type:Scholarly book

  2. 治療学 内科学総論 内科学書

    安藤雄一( Role: Contributor)

    中山書店  2019 

     More details

    Language:Japanese

  3. 薬物動態・薬力学.新臨床腫瘍学 がん薬物療法専門医のために

    安藤雄一( Role: Contributor)

    南江堂  2018 

     More details

    Language:Japanese

KAKENHI (Grants-in-Aid for Scientific Research) 16

  1. 抗がん薬による下痢・腸炎の病態解明と新治療法の開発

    2017.4 - 2020.3

    科学研究費補助金  基盤研究(C)

  2. がん薬物療法におけるサルコペニアの臨床的意義

    2014.4 - 2017.3

    科学研究費補助金  基盤研究(C)

      More details

    Authorship:Principal investigator 

  3. Exploring biomarkers for immune checkpoint inhibitors in elderly patients with cancer

    Grant number:22K07415  2022.4 - 2025.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Coinvestigator(s) 

  4. Study on proper use of oral anticoagulants combined with 5-fluorouracil

    Grant number:22K06743  2022.4 - 2025.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Coinvestigator(s) 

  5. Exploratory analysis of DNA methylation as a novel biomarker in gastrointestinal cancer chemotherapy

    Grant number:20K08328  2020.4 - 2024.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Coinvestigator(s) 

  6. Mechanism of predicting the effects of immune checkpoint inhibitors based on the diversity of cancer-associated fibroblasts

    Grant number:20H03528  2020.4 - 2023.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    Ando Yuichi

      More details

    Authorship:Principal investigator 

    Grant amount:\17290000 ( Direct Cost: \13300000 、 Indirect Cost:\3990000 )

    Meflin is a novel marker of cancer-associated fibroblasts (CAFs). In this study, we demonstrated that the prevalence of Meflin-positive CAFs correlates with favorable therapeutic effects to immune checkpoint inhibitors, using clinical specimens from patients with clear cell renal carcinoma and urothelial carcinoma. Furthermore, we clarified that the mechanism of tumor immunoregulation by this Meflin-positive CAF is the suppression of intratumor infiltration of CD11b-positive cells via complement C3 and its degradation product iC3b.

  7. がん薬物療法における抗がん薬曝露に対する科学的エビデンスの創出

    Grant number:19K07083  2019.4 - 2024.3

    科学研究費助成事業  基盤研究(C)

    満間 綾子, 安藤 雄一, 下方 智也

      More details

    Authorship:Coinvestigator(s) 

    新規抗がん薬の開発により、外来化学療法で取り扱う抗がん薬レジメンは増加する一方である。外来化学療法室の利用患者は年々増加し、多様なニーズに応えるがん薬物療法に習熟した医療者の関わりが重要となっている。がん薬物療法を専門とする医療者の育成、拡充にあたっては、専門的な教育・訓練とともに抗がん薬を扱う現場における医療者の安全、職場環境の整備も提唱されている。曝露防止のための機器開発が進む中で過去の報告は現状と乖離しており、医療者がコストと時間をかけてどこまで曝露対策を行うかの科学的実証は未確立である。本研究では、抗がん薬曝露の実態を経年的・経時的に調査し現状に即したエビデンスを創出する。
    本研究では、がん薬物療法における抗がん薬曝露の実態を調査し、繰り返しモニタリングを行うことで、国内での閾値の設定や予防の根拠となるエビデンスを創出することを目的としている。当院外来化学療法室では、院内すべての点滴抗がん薬の外来投与を専任の医療者が担当している。年間10,000件以上の実施にあたり、職業性曝露のモニタリングとして環境モニタリングと生物学的モニタリングの経年的実施を行う。
    <BR>
    <環境モニタリング>当院外来化学療法室での環境モニタリングを行うにあたり、モニタリングの手法、場所を絞り込んだ後に、抗がん薬曝露予防を目的とした機器導入、マニュアルの改訂・整備の現状を把握できている。閉鎖式薬物移送システム(closed system drug transfer device: CSTD) は、当院において抗がん薬のミキシングすべてには使用していない。揮発性抗がん薬にのみCSTDを使用している。これまでの経年的モニタリング結果では既報と比較して汚染の度合いを示す測定値は低く推移しており、継続してモニタリングを進めている。
    <生物学的モニタリング>外来化学療法室で実施する膀胱内注入後の抗がん薬曝露について、同意を得た患者および医療者の排尿より生物学的モニタリングを行う。ドキソルビシンの投与量、排尿回数など臨床薬理学的解析を加えて経時的変化を観察する予定であったが、昨年度同様、治療対象者が乏しい状況が続いている。
    <BR>
    がん関連学会での情報収集を継続した。2023年3月、第20回日本臨床腫瘍学会学術集会にて口頭発表を行っている。現地開催であり、発表の場では有用な質疑討論がなされた。
    環境モニタリングは順調に施行できている。新規薬剤の導入、併用レジメンの開発によりレジメン数は増えており、各がん種、個々の病状によって多様な抗がん薬治療が選択されている。COVID-19による診療体制の変化はあったが、外来化学療法室を利用する患者数は同程度で推移した。当初計画で予定した海外学会での発表機会はCOVID-19による診療体制の中では困難であった。オンラインでの学会参加と国内学会での現地発表となった。
    昨年同様、生物学的モニタリングは対象患者が乏しい状況であった。
    生物学的モニタリングの対象となる泌尿器疾患の患者は昨年同様乏しいことが予測される。がん薬物療法は新たな治療法の影響によって治療方針の変更はあり得るため、今後も対象患者があった場合には対応する。
    環境モニタリングは順調に遂行できており、学会発表や情報収集により得られた成果をふまえて論文化し発信する準備を進めている。新規薬剤の導入、併用レジメンの開発によって、がん薬物療法の現場で使用する対象薬剤や使用頻度は既報の状況とは大きく異なっている。従って、引き続き本研究の推進の価値があると研究代表者および研究分担者は一致している。今後も定期的に研究代表者および研究分担者間で意見交換を行い、研究の推進に努める。

  8. Factors involved in the efficacy and safety of biopharmaceuticals

    Grant number:19K07224  2019.4 - 2022.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Nakamura Katsunori

      More details

    Authorship:Coinvestigator(s) 

    Proper use and selection of antibody drugs are considered to be of clinical significance.The main purpose of this study was to clarify what causes side effects of biological drug and what is the most suitable combination drug for reducing side effects of biological drug.Infusion reactions are controlled by dosing rate, additional doses of corticosteroids, and prophylactic administration of antihistamines and antipyretic analgesics.We analyzed the correlation between the frequency of infusion reactions of rituximab and FcRn genetic polymorphisms.Furthermore, the difference between the combination drugs was examined.

  9. Mechanism of diarrhea/enteritis caused by anticancer drugs and development of new treatment

    Grant number:17K08950  2017.4 - 2020.3

    Ando Yuichi

      More details

    Authorship:Principal investigator 

    Grant amount:\3510000 ( Direct Cost: \2700000 、 Indirect Cost:\810000 )

    By focusing on bacterial-translocation, phenomenon in which human intestinal bacteria migrate into circulating blood in human body via intestinal wall, using highly-sensitive detection assay for viable bacteria, I investigated whether bacteria in the blood would be associated with the occurrence of adverse effects of cancer chemotherapy. The results revealed that patients with cancer were always prone to bacterial-translocations regardless of the administration of anticancer drugs, suggesting that bacterial-translocation would be the cause of febrile neutropenia, infection, and diarrhea/enteritis, which are caused by cancer chemotherapy.

  10. Screening and prevention of vascular events for cancer patients, and investigation of the mechanisms.

    Grant number:16K08906  2016.4 - 2020.3

    Mitsuma Ayako

      More details

    Authorship:Coinvestigator(s) 

    Some newly developed cancer chemotherapy drugs cause hemorrhage or thrombosis as adverse event through inhibition of angiogenesis. Prolonged survival and aging of cancer patients lead to increase of patients using anticoagulats to prevent cardiovascular disease. In this study we evaluated risk of cancer associated thrombosis receiving outpatient treatment, including drug interactions. We compared our data with predictive model proposed in foreign studies. We found no difference in outcome of treatment with specific anticoagulants. Effects of cancer chemotherapy and condition of patients influenced clinical course of thrombosis.

  11. Study of the infusion reaction by rituximab

    Grant number:16K08374  2016.4 - 2019.3

    Nakamura Katsunori

      More details

    Authorship:Coinvestigator(s) 

    Infusion reaction is a side effect that occurs immediately after antibody drug administration, and its prediction is becoming very important. In this study, we identified infusion reaction risk factors by analyzing genetic polymorphisms in patients who developed adverse effects immediately after rituximab administration. [Significance] By identifying risk factors such as the effects of FcRn genetic polymorphism, it is expected that the optimal use of rituximab can be considered taking into consideration individual differences in their genetic polymorphism. [Importance] It is expected that this study may be generalized to antibody drugs and could be applied to "preclinical tests" performed prior to clinical trials where antibody drugs are first administered to humans.

  12. Elucidation of sarcopenia mechanism in the cancer cachexia

    Grant number:15K08906  2015.4 - 2019.3

    Shimokata Tomoya

      More details

    Authorship:Coinvestigator(s) 

    We evaluated the body composition, muscle mass and adipose tissue, in patients who received cancer pharmacotherapy to test a hypothesis that the adipose tissue plays an important role in the process to cancer cachexia. We analyzed the change of the body composition in patients who received monotherapy of the mTOR inhibitor more than six months retrospectively. The muscle mass significantly decreased, but there were no significant changes in the adipose tissue quantity. Also, we performed a cohort study to evaluate a body composition change and a metabolic rate as subjects in the patients prospectively. We accumulate 28 cases and final analysis is in progress.

  13. Clinical significance of sarcopenia in cancer chemotherapy

    Grant number:26460626  2014.4 - 2018.3

    Ando Yuichi

      More details

    Authorship:Principal investigator 

    Grant amount:\3510000 ( Direct Cost: \2700000 、 Indirect Cost:\810000 )

    The aim of this study is investigated sarcopenia in cancer patients who underwent cancer chemotherapy in order to test the hypothesis that those patients with sarcopenia are more likely to experience severe toxicity and then poorly tolerate the treatment. First, we retrospectively analyzed the change of skeletal muscle mass in patients treated with an mTOR inhibitor and reported that the muscle mass was significantly reduced by treatment. Subsequently, an observational study was conducted to prospectively evaluate sarcopenia up to for 6 months in cancer patients who received a kinase inhibitor containing mTOR inhibitor. Of the 28 patients enrolled, 17 and 7 patients completed the 6-month and 3-month follow-ups, respectively. Final analysis of the results is in progress.

  14. Establishment of bone metastasis treatment by regulating hyaluronan network and osteoclast

    Grant number:26462261  2014.4 - 2018.3

    Urakawa Hiroshi

      More details

    Authorship:Coinvestigator(s) 

    Bone metastases impair the quality of patients with malignancies. We focused on the co-effect of regulation of hyaluronan (HA) and bone modifying agents. We investigated the effects of 4-methylumbelliferone (MU) and/or bone modifying agents on HA expression in breast and lung cancer cell lines in addition to their tumorigenicity in vitro and in vivo. MU or zoledronic acid treatment individually suppressed proliferation, migration and invasion of breast and lung cancer cell lines, and combination treatment of MU and zoledronic acid showed synergistic effects. Combination therapy showed additive inhibitory effects on metastatic bone lesions in vivo, which paralleled the inhibition of HA accumulation by MU, and inhibition of osteoclastogenesis. These data suggest that inhibition of HA synthesis is a promising novel therapeutic candidate for bone metastasis in addition to bone modifying agents.

  15. がん薬物療法における血管新生阻害薬の薬物効果予測因子としての眼底所見の探索的研究

    2011.4 - 2013.3

    科学研究費補助金  基盤研究(C)

      More details

    Authorship:Principal investigator 

  16. がん薬物療法における薬剤誘発性QT延長の遺伝的要因を含めた患者要因       

    2008.4 - 2011.3

    科学研究費補助金  基盤研究(C)

    安藤 雄一

      More details

    Authorship:Principal investigator 

▼display all